Phase 4 N=17 Bronchodilator Responsiveness in Obliterative Bronchiolitis
Obliterative Bronchiolitis
Primary: Per Cent Change of Forced Expiratory Volume in 1 Second (FEV1) After Bronchodilators — 14; 7 per cent positive change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,283 Airway Limitation Study: Study In Primary Care Centers Of Chronic Bronchitis In Long-Term Cigarette Smokers Of At Least 40 Years Of Age With Symptoms Of Cough And Shortness Of Breath
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With a Post-bronchodilator FEV1/FVC <=70% Versus Participants With a Postbronchodilator FEV1/FVC >70% — 308; 893 participants
Phase 3 N=122 GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs) — 120; 27 Participants
N/A N=38 Effects of Inspiratory Muscle Training in Patients With Bronchiectasis
Bronchiectasis
Primary: Maximum Inspiratory Pressure (MIP) and Maximum Expiratory Pressure (MEP) at 8 Weeks — 60; 71; 84; 69 cmH2O — p=0.005
Phase 2 N=98 Human Lung Responses to Respiratory Pathogens
Respiratory Infection
Primary: Antimicrobial Activity by Airway Surface Liquid (ASL) as Measured by Relative Light Units (RLU) — -581; -485 Relative Light Units (RLU)
Early Phase 1 N=17 Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung
Healthy · Latent Tuberculosis Infection (LTBI)
Primary: Median Difference in CD4 Cell Response to Intrabronchial Instillation of Tuberculin Purified Protein Derivative (PPD) — 5.26; 0.725; 29.9; 2.92 % Antigen Specific T…
N/A N=43 Association Between Increased Oxidative Stress, Anti-Inflammatory Fatty Acid Formation, and Airway Infection in People With Asthma and Chronic Obstructive Pulmonary Disease
Asthma · Pulmonary Disease, Chronic Obstructive
Primary: 8-isoprostane Levels as Biochemical Markers for Nonenzymatic Oxidative Stress in Asthma — 292.4; 421.8 pg/ml
N/A N=51 The Effects of Broccoli Sprout Extract on Obstructive Lung Disease
Asthma · COPD
Primary: The Primary Outcome is the Change in Bronchodilation and Bronchoprotection After Broccoli Sprout Extract — 10.3; 26.7 index
N/A N=28 Prophylactic Bronchoscopy After Inhalation Injury in Burn Patients
Inhalation Injury · Pneumonitis · Pneumonia
Primary: All Cause Mortality — 0; 1 participants
Phase 4 N=196 Prevention of OM-85 on Bronchiectasis Exacerbation
Bronchiectasis With Acute Exacerbation
Primary: Bronchiectasis Exacerbation — 0.98; 0.75 proportion of acute exacerbations
N/A N=21 Airway Inflammation in Congenital Diaphragmatic Hernia Patients
Congenital Diaphragmatic Hernia
Primary: Number of Participants With Elevated Sputum Eosinophils — 0 participants
Phase 3 N=274 Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis
Bronchiectasis
Primary: Change in QOL-B Respiratory Symptoms Score at Day 28 — 8.2; 3.2 units on a scale — p=0.011
Phase 3 N=266 Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis
Bronchiectasis
Primary: Change in QOL-B Respiratory Symptoms Score at Day 28 — 7.4; 5.7 units on a scale — p=0.68
Phase 4 N=20 Effect of Brovana and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)
COPD
Primary: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at 1 Week — 0.069; 0.010; 0.121; 0.023 Liters
Phase 4 N=78 Efficacy of Azithromycin in Treatment of Bronchiectasis
Bronchiectasis
Primary: 24 Hour Sputum Volume — 41.8; 23.6; 29.9; 26.2 gram — p=<0.01
N/A N=252 Chronic Obstructive Pulmonary Disease (COPD) Biomarker Identification Study
COPD
Primary: Spirometry Measurement: Percentage of Predicted Forced Expiratory Volume in 1 Second (FEV1 %Pred) — 75.572; 100.837; 108.311; 111.849 percent of predicted FEV1 — p=<0.0001
Phase 4 N=36 Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation
Chronic Obstructive Pulmonary Disease · COPD
Primary: Baseline Resting Cardiac Index (CI) — 2.4; 2.36 L/min/m^2 — p=0.85
N/A N=60 Leukocyte Function in Asthma and COPD
Asthma · COPD · Emphysema
Primary: Total Number of Inflammatory Cells Recovered in Sputum — 2.3; 2.1; 1.9; 5.2 10^6 cells/ml — p=0.1
N/A N=90,089 Comparative Effectiveness and Safety of Inhaled Corticosteroids and Antimicrobial Compounds for Non-CF Bronchiectasis
Bronchiectasis
Primary: Nontuberculous Mycobacterial (NTM) Disease — 188; 32 Events — p=0.19
Phase 2 N=25 Montelukast to Treat Bronchiolitis Obliterans
Bronchiolitis Obliterans · Chronic Graft Versus Host Disease · Leukotriene
Primary: Number of Participants With Stable or Improved Predicted Forced Expiratory Volume 1 (FEV-1) With Published Literature — 5; 7; 6; 1 Participants
N/A N=304 The Bronchiolitis Follow-up Intervention Trial
Bronchiolitis
Primary: Parental Anxiety — 4.2; 3.9 points on a scale
Phase 3 N=15 The Effects Of Bronchodilator Therapy On Respiratory And Autonomic Function In Patients With Familial Dysautonomia
Familial Dysautonomia
Primary: Change From Baseline of Forced Vital Capacity — 5.5; 4.7; 0.9 percentage change from baseline
N/A N=127 Infectious Pathogens in Acute Respiratory Illness in Adults and Elderly
Respiratory Disorders
Primary: Mean Estimated Number of Acute Exacerbation of COPD (AECOPD) — 3.04 AECOPD/subject/year
N/A N=126 The Natural History of Small Airways Physiology in Diseased and Healthy States
Asthma · COPD · Interstitial Lung Disease
Primary: FEV1 — 3.03; 2.32; 3.18; 2.76 L
Phase 4 N=80 Effect of OM-85 BV on Wheezing Related Morbidity in Children With Recurrent Wheezing
Asthma
Primary: Mean Rate of Wheezing Attacks — 3.57; 5.72 wheezing attacks/per patient — p=0.05
Phase 2 N=131 Evaluation of the Quality of Life Questionnaire-Bronchiectasis (QOL-B) in Patients With Bronchiectasis
Bronchiectasis
Primary: Reliability of the Respiratory Domain of the Quality of Life Questionnaire-Bronchiectasis (QOL-B) — 0.80 Intraclass Correlation Coefficient
N/A N=284 Bronchial Thermoplasty in Severe Persistent Asthma
Severe Asthma
Primary: Subjects Experiencing Severe Exacerbations (Rates) — 132; 118; 118; 106 Participants
Phase 2 N=32 Preliminary Study of Dornase Alfa to Treat Chest Infections Post Lung Transplant.
Lung Transplant Infection · Lower Respiratory Tract Infection
Primary: Lung Clearance Index 2% (LCI2%) — 10.68; 11.65; 10.09; 11.19 Index (change)
N/A N=115,397 Combined Bronchodilators in Chronic Obstructive Pulmonary Disease and the Risk of Adverse Cardio-pulmonary Events
Pulmonary Disease, Chronic Obstructive
Primary: Myocardial Infarction — 10.1; 11.3 No. of incident MI/1000patients/ year
N/A N=270 Comparison of Classification Standards of Bronchopulmonary Dysplasia (BPD) in Premature Infants
Bronchopulmonary Dysplasia
Primary: Respiratory Adverse Outcomes — 27; 60 Participants